REDWOOD CITY, Calif., Jan 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported that the company's Oncotype DX(R) breast cancer assay, used to predict the likelihood of disease recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients, has been included in the National Comprehensive Cancer Network (NCCN) 2008 Breast Cancer Treatment Guidelines. Oncotype DX is the only multi-gene expression assay to be recommended by NCCN, an alliance of 21 world-leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer. These guidelines were published online at http://www.nccn.org.
"We are pleased that NCCN, a leader in promoting quality cancer care, has included use of Oncotype DX for early-stage breast cancer patients," said Steven Shak, M.D., chief medical officer at Genomic Health. "With their recommendation, the recent inclusion of Oncotype DX in ASCO Guidelines and the majority of U.S. insured lives covered for Oncotype DX, it is clear the clinical community has accepted the test as standard practice for making individualized breast cancer treatment decisions."
Oncotype DX has been validated through multiple independent clinical studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Inclusion in NCCN's updated treatment guidelines, released today, reinforces the significance of molecular diagnostics in breast cancer treatment planning and in particular the value of the individualized information provided by Oncotype DX.
About Oncotype DX(R)
Oncotype DX is the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, nearly 7,000 physicians have ordered more than 40,000 tests, and health plans covering over 50 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. The American Society of Clinical Oncologists (ASCO) recommends the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the significance of molecular diagnostics in breast cancer treatment planning and the value of the individualized tumor information provided by Oncotype DX and the belief that the use of Oncotype DX has been accepted as standard practice for individualized breast cancer treatment decisions. These risks and uncertainties include, but are not limited to: the applicability of clinical results to actual outcomes; the ability of our test to continue to impact treatment decisions; our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; the risk of delay in developing new products or product enhancements; the risks and uncertainties associated with the regulation of our test by FDA; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the three-month period ended September 30, 2007. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.
Copyright (C) 2008 PR Newswire. All rights reserved
News Provided by COMTEX